Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 364
Filter
1.
Mol Psychiatry ; 23(2): 211-221, 2018 02.
Article in English | MEDLINE | ID: mdl-27777420

ABSTRACT

Here, we report a novel target of the drug memantine, ATP-sensitive K+ (KATP) channels, potentially relevant to memory improvement. We confirmed that memantine antagonizes memory impairment in Alzheimer's model APP23 mice. Memantine increased CaMKII activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term potentiation (LTP) and CaMKII activity was totally abolished by treatment with pinacidil, a specific opener of KATP channels. Memantine also inhibited Kir6.1 and Kir6.2 KATP channels and elevated intracellular Ca2+ concentrations in neuro2A cells overexpressing Kir6.1 or Kir6.2. Kir6.2 was preferentially expressed at postsynaptic regions of hippocampal neurons, whereas Kir6.1 was predominant in dendrites and cell bodies of pyramidal neurons. Finally, we confirmed that Kir6.2 mutant mice exhibit severe memory deficits and impaired hippocampal LTP, impairments that cannot be rescued by memantine administration. Altogether, our studies show that memantine modulates Kir6.2 activity, and that the Kir6.2 channel is a novel target for therapeutics to improve memory impairment in Alzheimer disease patients.


Subject(s)
Memantine/pharmacology , Potassium Channels, Inwardly Rectifying/drug effects , Alzheimer Disease/metabolism , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 2/drug effects , Dendrites , Disease Models, Animal , Hippocampus/drug effects , Humans , Long-Term Potentiation/drug effects , Memantine/metabolism , Memory/drug effects , Memory/physiology , Memory Disorders/drug therapy , Mice , Mice, Transgenic , Neurons , Phosphorylation , Potassium Channels/drug effects , Pyramidal Cells , Synapses , Temporal Lobe
2.
Benef Microbes ; 8(2): 309-321, 2017 Apr 26.
Article in English | MEDLINE | ID: mdl-28042704

ABSTRACT

The bovine intestinal epithelial cell line (BIE cells) expresses the Toll-like receptor (TLR)3 and is able to mount an antiviral immune response after the stimulation with poly(I:C). In the present study, we aimed to further characterise the antiviral defence mechanisms in BIE cells by evaluating the innate immune response triggered by rotavirus (RV) infection. In addition, we attempted to determine whether immunobiotic bifidobacteria are able to confer protection of BIE cells against RV infection by beneficially modulating the antiviral immune response. RV OSU (porcine) and UK (bovine) effectively infected BIE cells, while a significant lower capacity to infect BIE cells was observed for human (Wa) and murine (EW) RV. We observed that viral infection in BIE cells triggered TLR3/RIG-I-mediated immune responses with activation of IRF3 and TRAF3, induction of interferon beta (IFN-ß) and up-regulation of inflammatory cytokines. Our results also demonstrated that preventive treatments with Bifidobacterium infantis MCC12 or Bifidobacterium breve MCC1274 significantly reduced RV titres in infected BIE cells and differentially modulated the innate immune response. Of note, both strains significantly improved the production of the antiviral factor IFN-ß in RV-infected BIE cells. In conclusion, this work provides comprehensive information on the antiviral immune response of BIE cells against RV, that can be further studied for the development of strategies aimed to improve antiviral defences in bovine intestinal epithelial cells. Our results also demonstrate that BIE cells could be used as a newly immunobiotic evaluation system against RV infection for application in the bovine host.


Subject(s)
Bifidobacterium , Probiotics/pharmacology , Rotavirus Infections/immunology , Rotavirus Infections/therapy , Rotavirus/immunology , Animals , Cattle , Cell Line , Cytokines/biosynthesis , DEAD Box Protein 58/immunology , Enzyme Activation/drug effects , Epithelial Cells/immunology , Epithelial Cells/virology , Immunity, Innate/immunology , Interferon Regulatory Factor-3/metabolism , Interferon-beta/immunology , Intestinal Mucosa/cytology , Intestinal Mucosa/immunology , Intestinal Mucosa/virology , Rotavirus Infections/virology , TNF Receptor-Associated Factor 3/metabolism , Toll-Like Receptor 3/immunology
3.
Int J Oral Maxillofac Surg ; 44(4): 483-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25439132

ABSTRACT

Aqua Titan (AT), comprising microscopic titanium particles dispersed in water, has been reported to have beneficial effects on muscle tissue. This study investigated the effects of local application of AT on symptoms in patients with muscle disorders of the temporomandibular joint (TMJ) compared to patients with joint disorders of the TMJ. Sixteen patients with unilateral masseter muscle pain during motion (muscle disorder group) and six patients with unilateral TMJ pain during motion (joint disorder group) applied an AT-permeated patch over the painful area every night for 2 weeks. Symptoms were evaluated clinically at the initial visit and 1 and 2 weeks later. Clinical symptoms in the joint disorder group showed no tendency towards improvement after 2 weeks. In contrast, mouth opening range with/without pain, visual analogue scale (VAS) scores for pain during mouth opening and eating, and activities of daily living (ADL) scores in the muscle disorder group were improved significantly after 2 weeks. Multiple comparison tests in the muscle disorder group showed significant improvements in the VAS for eating and ADL score after 1 week. These results suggest that the AT patch has a potential supplementary role in the treatment of patients with muscle disorders of the TMJ.


Subject(s)
Masseter Muscle , Temporomandibular Joint Disorders/drug therapy , Titanium/pharmacology , Activities of Daily Living , Administration, Topical , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Pain Management , Pain Measurement , Titanium/administration & dosage , Treatment Outcome
4.
Curr Oncol ; 21(6): e782-9, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25489268

ABSTRACT

Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patient with a gemcitabine-based regimen as postoperative adjuvant chemotherapy, after which she achieved at least 7 years of progression-free survival, an extremely long duration given the aggressive features of this tumour. We retrospectively performed immunohistochemical analyses and fluorescence in situ hybridization to make a pathology diagnosis and to investigate the tumour features. MYC amplification and c-Myc protein overexpression were positively detected. It might be possible to correlate the effectiveness of the gemcitabine-based chemotherapeutic regimen with MYC gene amplification and c-Myc protein overexpression.

5.
J Acoust Soc Am ; 136(3): 1085, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25190384

ABSTRACT

Due to limitations of computers, prediction of structure-borne sound remains difficult for large-scale problems. Herein a prediction method for low-frequency structure-borne sound transmissions on concrete structures using the finite-difference time-domain scheme is proposed. The target structure is modeled as a composition of multiple plate elements to reduce the dimensions of the simulated vibration field from three-dimensional discretization by solid elements to two-dimensional discretization. This scheme reduces both the calculation time and the amount of required memory. To validate the proposed method, the vibration characteristics using the numerical results of the proposed scheme are compared to those measured for a two-level concrete structure. Comparison of the measured and simulated results suggests that the proposed method can be used to simulate real-scale structures.

6.
Horm Metab Res ; 46(11): 814-8, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24977657

ABSTRACT

The aim of the present study was to determine whether the dipeptidyl peptidase (DPP)-4 inhibitor could repair pancreatic ß-cell dysfunction and insulin resistance. Ten subjects with type 2 diabetes who had never received DPP-4 inhibitor treatment were enrolled in the study. Just before and 3 months after twice-daily administration of vildagliptin (50 mg tablets), insulin secretion and insulin sensitivity were estimated using 2-compartment model analysis of C-peptide kinetics and insulin-modified minimal model parameters, respectively. The first-phase insulin secretion (CS1) was determined as the sum of the C-peptide secretion rate (CSR) from 0 to 5 min (normal range 6.8-18.5 ng/ml/min). The whole-body insulin sensitivity index (SI) was calculated using a minimal model software program (normal range 2.6-7.6×10(-4)/min/µU/ml). After vildagliptin treatment, reductions in mean (± SE) HbA1c were noted (43.28±1.53 vs. 40.98±1.77 mmol/mol; p=0.019). Vildagliptin treatment increased the area under the curve for the C peptide reactivity (CPR) (AUCCPR; 26.66±5.15 vs. 33.02±6.12 ng/ml · 20 min; p=0.003) and CS1 (0.80±0.20 vs. 1.35±0.38 ng/ml/min; p=0.037) in response to an intravenous glucose load. -Vildagliptin treatment significantly increased SI (0.46±0.27 vs. 1.21±0.48×10(-4)/min/µU/ml; p=0.037). The long-term administration of vildagliptin improved CS1 and Si suggesting that this drug has the capacity to repair impairments in pancreatic ß-cell function and insulin resistance in type 2 diabetes.


Subject(s)
Adamantane/analogs & derivatives , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Insulin Resistance , Insulin-Secreting Cells/pathology , Nitriles/pharmacology , Pyrrolidines/pharmacology , Adamantane/pharmacology , Area Under Curve , C-Reactive Protein/metabolism , Fasting , Female , Glucose Tolerance Test , Humans , Insulin/metabolism , Insulin Secretion , Insulin-Secreting Cells/drug effects , Male , Middle Aged , Vildagliptin
7.
Oncogene ; 32(34): 4034-42, 2013 Aug 22.
Article in English | MEDLINE | ID: mdl-22964644

ABSTRACT

KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in NSCLC therapy. We recently identified epiregulin (EREG) as one of several putative transcriptional targets of oncogenic KRAS signaling in both KRAS-mutant NSCLC cells and immortalized bronchial epithelial cells expressing ectopic mutant KRAS. In the current study, we found that EREG is overexpressed in NSCLCs harboring KRAS, BRAF or EGFR mutations compared with NSCLCs with wild-type KRAS/BRAF/EGFR. Small interfering RNAs (siRNAs) targeting mutant KRAS, but not an siRNA targeting wild-type KRAS, significantly reduced EREG expression in KRAS-mutant and EREG-overexpressing NSCLC cell lines. In these cell lines, EREG expression was downregulated by MEK and ERK inhibitors. Importantly, EREG expression significantly correlated with KRAS expression or KRAS copy number in KRAS-mutant NSCLC cell lines. Further expression analysis using 89 NSCLC specimens showed that EREG was predominantly expressed in NSCLCs with pleural involvement, lymphatic permeation or vascular invasion and in KRAS-mutant adenocarcinomas. In addition, multivariate analysis revealed that EREG expression is an independent prognostic marker and EREG overexpression in combination with KRAS mutations was associated with an unfavorable prognosis for lung adenocarcinoma patients. In KRAS-mutant and EREG overexpressing NSCLC cells, siRNA-mediated EREG silencing inhibited anchorage-dependent and -independent growth and induced apoptosis. Our findings suggest that oncogenic KRAS-induced EREG overexpression contributes to an aggressive phenotype and could be a promising therapeutic target in oncogenic KRAS-driven NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Epidermal Growth Factor/genetics , Lung Neoplasms/genetics , Proto-Oncogene Proteins/genetics , ras Proteins/genetics , Aged , Apoptosis/genetics , Butadienes/pharmacology , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line , Cell Line, Tumor , Epidermal Growth Factor/metabolism , Epiregulin , ErbB Receptors/genetics , Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Male , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Mutation , Nitriles/pharmacology , Phenotype , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins p21(ras) , Pyrazoles/pharmacology , Pyridazines/pharmacology , RNA Interference , ras Proteins/metabolism
8.
Curr Med Chem ; 19(30): 5164-9, 2012.
Article in English | MEDLINE | ID: mdl-22934768

ABSTRACT

The molecular mechanisms that regulate the proliferation and differentiation of induced pluripotent stem (iPS) cells are of great interest. However, whether stimulation with nicotine enhances the proliferation and differentiation of iPS cells has not been investigated. In the present study, western blot analysis revealed that the α4-nAchR and α7-nAchR are expressed in mouse iPS cells. Mouse iPS cells were treated with nicotine for 24 h under feeder-free conditions. Mouse iPS cells were guided to differentiate into mesodermal progenitor cells on type IV collagen (Col IV)-coated dishes in differentiation medium. Mouse iPS cells were guided to differentiate into neural progenitor cells by embryoid body (EB) formation on ultra-low-attachment dishes. After 4 days of growth, all-trans retinoic acid (ATRA; 1 µM) or nicotine (300 nM) was added to the EB cultures and maintained for additional 4 days and plated onto fibronectincoated plates. A BrdU incorporation assay showed that treatment with 300 nM nicotine significantly increased the DNA synthesis of mouse iPS cells or mouse iPS cell-derived mesodermal progenitor cells. This effect was significantly inhibited by pretreatment with an α4-nAchR antagonist, an α7-nAchR antagonist, or a CaMKII inhibitor. The differentiation potential of mouse iPS cells into mesodermal progenitor cells or neural progenitor cells was not affected by the nicotine treatment. The present study indicates that stimulation of the α4-nAchR and α7-nAchR may lead to a significant increase in the proliferation of mouse iPS cells or mouse iPS cell-derived mesodermal progenitor cells through the CaMKII signaling pathway.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Induced Pluripotent Stem Cells/drug effects , Nicotine/pharmacology , Nicotinic Agonists/pharmacology , Receptors, Nicotinic/metabolism , Animals , Benzylamines/pharmacology , Bungarotoxins/pharmacology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/antagonists & inhibitors , Cell Differentiation/drug effects , Cell Line , Cell Proliferation/drug effects , Cells, Cultured , Dihydro-beta-Erythroidine/pharmacology , Induced Pluripotent Stem Cells/cytology , Induced Pluripotent Stem Cells/metabolism , Mice , Nicotinic Antagonists/pharmacology , Protein Kinase Inhibitors/pharmacology , Sulfonamides/pharmacology
9.
Allergy ; 66(9): 1183-92, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21545428

ABSTRACT

BACKGROUND: Glutathione redox status, changes in intracellular reduced (GSH) or oxidized (GSSG) glutathione, plays a significant role in various aspects of cellular function. In this study, we examined whether intracellular glutathione redox status in human dendritic cells (DCs) regulates the polarization of Th1/Th2 balance. METHODS: Human monocyte-derived DCs (MD-DCs) treated with glutathione reduced form ethyl ester (GSH-OEt) or L-buthionine-(S,R)-sulfoximine (BSO) were stimulated by lipopolysaccharide (LPS), and the levels of polarization cytokines were measured. Next, DCs matured by LPS or thymic stromal lymphopoietin (TSLP) were cocultured with allogeneic CD4(+) naive T cells and Th1/Th2 balance was evaluated by cytokine production from the primed T cells. RESULTS: Monocyte-derived DCs exposed to GSH-OEt and BSO had increased and decreased intracellular GSH contents, respectively. Lipopolysaccharide-induced interleukin (IL)-27 production was enhanced by GSH-OEt and suppressed by BSO, but neither GSH-OEt nor BSO affected the expression of HLA-DR, CD80, CD83, or CD86. Mature GSH-OEt-treated MD-DCs enhanced interferon (IFN)-γ production from CD4(+) T cells compared with nontreated MD-DCs, and small interfering RNA (siRNA) against IL-27 suppressed the effect of GSH-OEt on IFN-γ production. Additionally, although human myeloid DCs activated by TSLP (TSLP-DCs) prime naïve CD4(+) T cells to differentiate into Th2 cells, treatment of TSLP-DCs with GSH-OEt reduced IL-13 production and enhanced IFN-γ production by CD4(+) T cells. Interleukin-27 siRNA attenuated the inhibitory effect of GSH-OEt on Th2 polarization. CONCLUSION: Our results reveal that Th1 and Th2 responses are controlled by intracellular glutathione redox status in DCs through IL-27 production.


Subject(s)
Dendritic Cells/immunology , Glutathione/metabolism , Interleukin-17/biosynthesis , T-Lymphocytes/immunology , Cell Differentiation/immunology , Cytokines/biosynthesis , Dendritic Cells/drug effects , Glutathione/analogs & derivatives , Glutathione/pharmacology , Humans , Intracellular Space/metabolism , Lipopolysaccharides/immunology , Oxidation-Reduction , T-Lymphocytes/cytology , Th1 Cells/immunology , Th2 Cells/immunology
10.
Int J Immunopathol Pharmacol ; 23(2): 449-61, 2010.
Article in English | MEDLINE | ID: mdl-20646340

ABSTRACT

Regulatory T cells (Treg) play a critical role in immune homeostasis and expansion of Treg is controlled by chemokine receptors. The chemokine CXCL12 and its G-protein-coupled receptor (CXCR4) are involved in the development of idiopathic pulmonary fibrosis (IPF), but the association of Treg with the CXCL12/CXCR4 axis has not been documented. The aim of this study is to determine the distribution and extent of CXCL12/CXCR4 expression in idiopathic type of pulmonary fibrosis, and the relation of Treg expansion in the interstitium of pulmonary fibrosis patients to CXCL12/CXCR4 expression. CXCL12 expression was examined by immunostaining and ELISA in tissue specimens from patients with usual interstitial pneumonia (UIP, n=15), patients with fibrotic non-specific interstitial pneumonia (f-NSIP, n=4), and controls (n=6). CXCR4 expression was examined by in situ hybridization and immunoblotting. Expression of CD45, CD3, CD20, transcription factor forkhead box P3 (FOXP3), and CD25 was assessed by immunostaining. Fibrosis was evaluated by determining the established fibrosis (EF) score. The CXCL12/CXCR4 axis was upregulated in UIP and f-NSIP, and CXCL12 derived from lung tissue attracted CXCR4(+) cells. CXCR4(+) cells showed a CD3(+) cell distribution pattern. The interstitial FOXP3(+)/CD3(+) and CD25(+)/CD3(+) cell ratios were lower in UIP than f-NSIP, but the CXCR4(+)/CD3(+) cell ratio was not different. The FOXP3(+)/CD3(+) cell ratio and EF score were inversely correlated. These findings suggest that the CXCL12/CXCR4 axis contributes to inflammation in UIP and f-NSIP by promoting the accumulation CXCR4(+) lymphocytes, and a decrease of Treg is correlated with the severity of fibrosis in UIP.


Subject(s)
Chemokine CXCL12/physiology , Forkhead Transcription Factors/analysis , Idiopathic Pulmonary Fibrosis/immunology , Receptors, CXCR4/physiology , T-Lymphocytes, Regulatory/physiology , Adult , Aged , Benzylamines , Cyclams , Female , Heterocyclic Compounds/pharmacology , Humans , Male , Middle Aged , Pulmonary Fibrosis/etiology
11.
Int J Immunopathol Pharmacol ; 23(1): 1-11, 2010.
Article in English | MEDLINE | ID: mdl-20377990

ABSTRACT

To prevent and control disease caused by exposure to various agents, it is necessary to determine the harmful level of intervention and to establish a method for measuring that level. In-air microparticle-induced X-ray emission (in-air micro-PIXE) analysis is based on irradiation of specimens with a proton ion microbeam, and has been modified for biological application. Two-dimensional analysis and quantitative analysis using the system confirmed that asbestos induced apoptosis by upregulating Fas expression and also revealed the accumulation of CD163-expressing macrophages in the lungs of patients with asbestosis. By quantitative comparison of the area of Fas or CD163 expression and the Fas- or CD163-negative area in asbestos lung tissue, the harmful levels which caused the expression of Fas or CD163 could be estimated on Silica, Ferrous iron, and Magnesium (the components of asbestos) deposition. These results indicate that the system could be useful for investigating the pathogenesis of inhaled particle-induced immune reactions and for determining harmful levels of exogenous agents.


Subject(s)
Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Asbestos/analysis , Asbestosis/immunology , Lung/chemistry , Receptors, Cell Surface/analysis , Spectrometry, X-Ray Emission/methods , fas Receptor/analysis , Aged , Asbestosis/metabolism , Asbestosis/pathology , Humans , Immunohistochemistry , Male
12.
Int J Immunopathol Pharmacol ; 23(1): 153-64, 2010.
Article in English | MEDLINE | ID: mdl-20378003

ABSTRACT

Interactions between CXCL12 and its receptors CXCR4 or CXCR7 are involved in tumor growth and metastasis in various types of human cancer. However, CXCL12 expression and its role in lung cancer are not fully elucidated. Here we examined the expression of CXCL12 in 54 lung cancer cell lines consisting of 23 small cell lung cancers (SCLCs) and 31 non-small cell lung cancers (NSCLCs). CXCL12 was overexpressed in lung cancer cell lines compared to non-malignant human bronchial epithelial cell lines (N = 6). CXCL12 expression was positively but weakly correlated with the expression of CXCR4 or CXCR7. We also examined CXCL12 expression in 89 NSCLC specimens and found that CXCL12 expression was significantly higher in tumor specimens from female patients, non-smokers and adenocarcinoma patients. Small interfering RNAs targeting CXCL12 inhibited cellular proliferation, colony formation and migration of CXCL12-overexpressing lung cancer cells; however, this inhibition did not occur in lung cancer cells that lacked CXCL12. Furthermore, the anti-CXCL12 neutralizing antibody mediated inhibitory effects in three lung cancer cell lines that overexpressed CXCL12, but not in two CXCL12 non-expressing lung cancer cell lines nor two non-malignant bronchial epithelial cell lines. The present study demonstrates that: CXCL12 is concomitantly overexpressed with CXCR4 or CXCR7 in lung cancers; CXCL12 is highly expressed in NSCLCs from females, non-smokers and adenocarcinoma patients; and disruption of CXCL12 inhibits the growth and migration of lung cancer cells. Our findings indicate that CXCL12 is required for tumor growth and provide a rationale for the anti-CXCL12 treatment strategy in lung cancer.


Subject(s)
Chemokine CXCL12/physiology , Lung Neoplasms/pathology , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Cell Movement , Cell Proliferation , Chemokine CXCL12/antagonists & inhibitors , Chemokine CXCL12/genetics , ErbB Receptors/physiology , Female , Humans , Lung Neoplasms/immunology , Lung Neoplasms/therapy , Male , RNA, Messenger/analysis , RNA, Small Interfering/genetics , Receptors, CXCR/genetics , Receptors, CXCR4/genetics
13.
J Biol Regul Homeost Agents ; 24(1): 99-102, 2010.
Article in English | MEDLINE | ID: mdl-20385076

ABSTRACT

The present case showed eosinophilic bronchiolitis and sinusitis with an overexpression of carcinoembryonic antigen (CEA) in lung and sinus and an elevation of serum CEA level, both of which were improved by oral steroid therapy. A 54-year-old asthmatic woman had developed a shortness of breath on exertion, and the chest X-ray revealed diffuse centrilobular shadows. Her serum CEA level had increased gradually. Eosinophil infiltration and overexpression of CEA were demonstrated in both the lung and sinus by immunohistochemistry. Both the lung and sinus lesions, and the serum CEA level were improved by oral steroid therapy. No evidence of tumor was found by extensive examination. From this case, eosinophilic bronchiolitis was considered to be an airway disease like "eosinophilic sinobronchiolitis" through the common pathophysiology of CEA, and serum CEA level was a good marker of disease condition.


Subject(s)
Bronchiolitis/diagnosis , Carcinoembryonic Antigen/metabolism , Eosinophilia/diagnosis , Asthma/complications , Bronchioles/metabolism , Bronchiolitis/complications , Bronchiolitis/drug therapy , Bronchiolitis/metabolism , Carcinoembryonic Antigen/blood , Eosinophilia/complications , Eosinophilia/drug therapy , Eosinophilia/metabolism , Female , Glucocorticoids/therapeutic use , Humans , Middle Aged , Paranasal Sinuses/metabolism , Prednisolone/therapeutic use , Sinusitis/complications , Sinusitis/diagnosis , Sinusitis/drug therapy , Sinusitis/metabolism
14.
Neurogastroenterol Motil ; 22(6): 611-e172, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20236246

ABSTRACT

BACKGROUND: It has been reported that the prevalence of gastroesophageal reflux (GER) disease is high in patients with obstructive sleep apnea (OSA). End-inspiratory intra-esophageal pressure decreases progressively during OSA, which has been thought to facilitate GER in OSA patients. The aim of our study was to clarify the mechanisms of GER during sleep (sleep-GER) in OSA patients. METHODS: Eight OSA patients with reflux esophagitis (RE), nine OSA patients without RE, and eight healthy controls were studied. Polysomnography with concurrent esophageal manometry and pH recording were performed. KEY RESULTS: Significantly more sleep-GER occurred in OSA patients with RE than without RE or in controls (P < 0.05). The severity of OSA did not differ between OSA patients with RE and without RE. Sleep-GER was mainly caused by transient lower esophageal sphincter relaxation (TLESR), but not by negative intra-esophageal pressure during OSA. During OSA gastroesophageal junction pressure progressively increased synchronous to intra-esophageal pressure decrease. OSA patients had significantly more TLESR events during sleep related to preceding arousals and shallow sleep, but the number of TLESR events was not related to RE. CONCLUSIONS & INFERENCES: In OSA patients, sleep-GER was mainly caused by TLESR, but not by negative intra-esophageal pressure due to OSA.


Subject(s)
Gastroesophageal Reflux/etiology , Gastroesophageal Reflux/physiopathology , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/physiopathology , Adult , Aged , Arousal/physiology , Esophageal Sphincter, Lower/physiopathology , Esophagitis, Peptic/complications , Esophagitis, Peptic/physiopathology , Esophagus/physiopathology , Female , Humans , Hydrogen-Ion Concentration , Male , Manometry , Middle Aged , Polysomnography , Sleep Stages/physiology , Young Adult
15.
Kyobu Geka ; 62(6): 509-12, 2009 Jun.
Article in Japanese | MEDLINE | ID: mdl-19522216

ABSTRACT

An 83-year-old woman was referred to our hospital to examine for an infiltration shadow in the right lower lobe with progressive bronchorea Computed tomography showed an infiltration lesion with the longest diameter of 10 cm in the right lower lobe and a tumor with the longest diameter of 3 cm in the middle lobe. Serum level of carbohydrate antigen (CA) 19-9 markedly increased to 37,670 U/ml over a period of 3 months. The pathologic study obtained by a transbronchial tumor biopsy revealed a mucinous adenocarcinoma The patient underwent video-assisted thoracoscopic right middle and lower bi-lobectomies with nodal sampling. Postoperative course was uneventful Pathologic study revealed an adenocarcinoma with mixed subtypes, predominantly composed of mucinous bronchiolo-alveolar cell carcinoma (BAC). Immunohistochemical study showed CA19-9 positivity in the apical surface of some tumor cells and diffuse patterns of other tumor cells. Postoperative course was uneventful and serum CA19-9 levels decreased within the normal range. Clinico-pathologic features of the lung cancer patients with serum elevation of CA19-9 and CA19-9 positivity in the cancer cells was discussed. CA19-9 can be an useful tumor marker in the selected patients with mucinous BAC.


Subject(s)
Adenocarcinoma, Bronchiolo-Alveolar/diagnosis , Biomarkers, Tumor/blood , CA-19-9 Antigen/blood , Lung Neoplasms/diagnosis , Adenocarcinoma, Bronchiolo-Alveolar/pathology , Adenocarcinoma, Bronchiolo-Alveolar/surgery , Aged, 80 and over , Diagnostic Imaging , Female , Humans , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Lymph Node Excision , Pneumonectomy , Treatment Outcome
16.
Am J Transplant ; 9(3): 567-77, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19260836

ABSTRACT

The impact of acute antibody-mediated rejection (AAMR) on the long-term outcome on ABO-incompatible (ABOI) kidney transplantation is not well understood. We retrospectively analyzed the long-term impact of AAMR and risk factors for AAMR in 57 consecutive recipients performed between 1999 and 2004. Nineteen patients (33%) who developed AAMR within 3 months posttransplantation constituted of the AMR group. The graft survival rate was significantly lower in the AMR group (AMR vs. non-AMR, respectively; 5 years: 84% vs. 95%; 8 years: 45% vs. 95%; p = 0.009). The prevalence of transplant glomerulopathy at 1 year posttransplantation was significantly higher in the AMR group (AMR 64% vs. non-AMR 3%, p < 0.001). Multivariate analysis demonstrated that anti-blood group IgG antibody titers of 1:32 at the time of transplantation (OR, 9.52; p = 0.041) and donor-specific anti-HLA antibodies (DSHA) detected by Luminex single bead method (OR, 5.68; p = 0.015) were independent risk factors for AAMR regardless of baseline anti-blood group IgG antibody titers. Our results indicate that AAMR has a heavy impact on the long-term outcome and preoperative DSHA appears to have a more significant association with poor graft outcomes than anti-blood group antibodies, even in ABOI kidney transplantation.


Subject(s)
ABO Blood-Group System/immunology , Antibodies/immunology , Blood Group Incompatibility/immunology , Graft Rejection/immunology , Kidney Transplantation/immunology , Adult , Creatine/blood , Female , Follow-Up Studies , Humans , Male , Risk Factors
17.
Int J Immunopathol Pharmacol ; 22(1): 43-51, 2009.
Article in English | MEDLINE | ID: mdl-19309551

ABSTRACT

CXCL12 is a chemokine that binds to a G-protein-coupled receptor (CXCR4). CXCL12 is expressed in various tumors and is considered as playing an important role in tumor growth and invasion. The aim of this study is to investigate the expression of CXCL12 in human malignant mesothelioma (MM), the chemotactic effect of CXCL12 derived from MM, and the expression of CXCR4 in MM tissues in relation to regulatory T cells. CXCL12 expression was examined by immunostaining of tissue specimens from malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPEM). The MM group comprised 6 patients (4 men/2 women, MPM=4, MPEM=2, aged 56.0 +/- 12.4 years) and the control (non-mesothelioma) group also had 6 patients (4 men/2 women aged 65.0 +/- 6.7 years). CXCL12 mRNA expression was also examined by RT-PCR in MPM cell lines (H28, H2052, and H2058), while CXCR4 mRNA expression was examined by in situ hybridization in MPM tissue. CXCL12 was expressed in the cytoplasm of MM cells from all patients, but was not expressed in the control group. H2052 and H2058 cells expressed CXCL12 mRNA, but H28 cells did not. CXCL12 in MM tissue homogenate supernatant had a chemotactic effect on CXCR4-expressing THP-1 cells. CXCR4 mRNA was expressed by a part of LCA+CD3+ Foxp3+CD25+ T cells that were located adjacent to the border of CXCL12-expressing epithelioid MPM. These findings suggest that CXCL12 contributed to tumor-related inflammation by inducing the accumulation of CXCR4-expressing cells with regulatory T cell markers around MM.


Subject(s)
Chemokine CXCL12/analysis , Forkhead Transcription Factors/analysis , Interleukin-2 Receptor alpha Subunit/analysis , Mesothelioma/immunology , Pleural Neoplasms/immunology , Receptors, CXCR4/analysis , Aged , Cell Line, Tumor , Female , Humans , Male , Mesothelioma/pathology , Middle Aged , Pleural Neoplasms/pathology , RNA, Messenger/analysis , Receptors, CXCR4/genetics
18.
Endoscopy ; 41(1): 25-8, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19160155

ABSTRACT

BACKGROUND AND STUDY AIMS: Saline as an injection solution for endoscopic resection techniques has several disadvantages such as a short-lasting effect leading to a potentially higher risk of bleeding and perforation. The new substance of photocrosslinkable chitosan hydrogel in a DMEM/F12 medium (PCH) can be converted into an insoluble hydrogel by ultraviolet irradiation for 30 s, and was evaluated in two sets of animal experiments. METHODS: 18 pigs were used in the two parts of the study. First, mucosal resections were done with either PCH or hypertonic saline; the effects of both agents on wound healing were examined endoscopically and histologically. Second, in vivo degradation of PCH was examined using six pig stomachs. RESULT: PCH injection led to a longer-lasting elevation with clearer margins, compared with hypertonic saline, thus enabling precise endoscopic submucosal dissection (ESD) along the margins of the elevated mucosa. The endoscopic appearance after ESD was similar in both groups. PCH biodegradation was completed within 8 weeks according to endoscopic and histologic analyses. CONCLUSION: PCH is a promising agent for submucosal injection prior to various techniques of endoresection. It should be evaluated in clinical trials after biocompatibility testing for PCH is completed.


Subject(s)
Biocompatible Materials , Chitosan , Hydrogels/administration & dosage , Intestinal Mucosa/surgery , Wound Healing/drug effects , Animals , Biocompatible Materials/pharmacokinetics , Chitosan/pharmacokinetics , Cross-Linking Reagents , Dissection , Endoscopy , Feasibility Studies , Hydrogels/pharmacokinetics , Injections , Male , Models, Animal , Sodium Chloride/administration & dosage , Swine , Treatment Outcome
20.
Int J Immunopathol Pharmacol ; 21(1): 251-3, 2008.
Article in English | MEDLINE | ID: mdl-18336755

ABSTRACT

Churg-Strauss syndrome (CSS) is characterized by asthma and/or a history of allergy, eosinophilia and an often life-threatening systemic necrotizing vasculitis. We describe a patient with CSS and hypoxemia with a high alveolar-arterial oxygen gradient (AaDO2), but no pulmonary parenchymal involvement. The patient also had a low diffusion capacity with normal lung volume and a high level of serum thrombomodulin, a marker of endothelial cell injury. Treatment for CSS, such as corticosteroid, improved both hypoxemia and AaDO2 consistent with amelioration of diffusion capacity and serum thrombomodulin level, suggesting that this pathosis involves microangiopathy with endothelial cell damage induced by vasculitis in pulmonary blood vessels.


Subject(s)
Churg-Strauss Syndrome/complications , Hypoxia/etiology , Oxygen/metabolism , Pulmonary Alveoli/metabolism , Pulmonary Gas Exchange , Adult , Arteries , Churg-Strauss Syndrome/drug therapy , Churg-Strauss Syndrome/metabolism , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...